Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 27, 2021updated 24 Jun 2021 3:10pm

Thoma Bravo to acquire trial financial solutions firm Greenphire

The investment from Thoma Bravo is set to support Greenphire’s growth and expansion in trial financial process automation space.

Private equity firm Thoma Bravo has agreed to acquire Greenphire, which provides software for managing the financial lifecycle of clinical trials, from The Riverside Company.

Financial details of the acquisition were not disclosed.

Greenphire was founded in 2008 to support global pharmaceutical companies to conduct clinical trials. It offers solutions for the automation of the trial financial process.

These solutions are designed to improve trial performance by optimising payment and logistical workflows from sponsors and contract research organisations (CROs) to sites and patients in about 70 countries.

Sponsors, CROs and research sites can leverage the company’s SaaS solution suite for trials of all designs and complexities. Greenphire also provides solutions to simplify travel for sites and patients.

In January last year, Greenphire expanded its global travel solution, ConneX, to include additional in-market support and travel visa fulfilment services.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Greenphire CEO Jim Murphy said: “Our acquisition by Thoma Bravo is further validation of our strategy and the unique value we provide our clients, particularly as pharmaceutical companies and CROs accelerate trends towards participant centricity in their clinical trials.

“We have continued to set the standard for financial workflow automation and patient convenience in clinical trials on a global scale and look forward to building on our growth and success during this new chapter with Thoma Bravo.”

The investment from Thoma Bravo is expected to support Greenphire’s growth and expansion.

Thoma Bravo partner Hudson Smith said: “The Covid-19 pandemic has underscored the importance of clinical trial technology solutions which enable greater research site effectiveness and better participant support.

“Greenphire is well-positioned to expand its client base and continue to execute on its growth strategy.”

Subject to customary regulatory approvals, the transaction is set to complete in the coming months.

After closing, Greenphire CEO Jim Murphy will continue to run the company along with the current management team in King of Prussia, Pennsylvania, US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy